Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Brainsway ( (BWAY) ).
Brainsway Ltd. has announced its Annual General Meeting of Shareholders, scheduled for September 11, 2025, in Jerusalem, Israel. The meeting will address key proposals, including the appointment of Kost Forer Gabbay & Kasierer as the company’s independent auditors for 2025, the re-election of board members, and the approval of updated compensation and equity grants for CEO Hadar Levy. This meeting is significant for stakeholders as it will influence the company’s governance and financial oversight for the coming year.
The most recent analyst rating on (BWAY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
Brainsway’s strong financial performance and positive earnings call guidance significantly contribute to its overall score. While the technical indicators show moderate bullish momentum, the high P/E ratio and absence of a dividend yield are valuation concerns.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
Brainsway Ltd. operates in the medical technology industry, focusing on the development and provision of advanced non-invasive treatment solutions for brain disorders. The company is known for its Deep Transcranial Magnetic Stimulation (Deep TMS) devices, which are used to treat various mental health conditions, including depression and obsessive-compulsive disorder.
Average Trading Volume: 44,938
Technical Sentiment Signal: Buy
Current Market Cap: $217.4M
Learn more about BWAY stock on TipRanks’ Stock Analysis page.